← Human Trials & Peer-Reviewed Studies
Growth hormone and outcome in patients with intracerebral hemorrhage: a pilot study.
Plain-language guide to PMID 21812576 (2011): pilot clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 40 patients.
Key Facts
- PMID
- 21812576
- Journal
- Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
- Year
- 2011
- Study type
- Clinical Trial
- Authors
- Zweifel C et al. (7 authors)
- DOI
- 10.3109/1354750X.2011.599074
- Registered trial
- NCT00390962
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.
Endocrine alterations of the hypothalamic-pituitary-axis are one of the first measurable physiological changes in cerebral insults.
Within this pilot study, the researchers evaluated the prognostic value of GH in patients with acute intracerebral hemorrhage (ICH).
Who Took Part
According to the abstract, 40 patients were involved.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
In a prospective observational study in 40 consecutive patients with ICH, GH was measured on admission.
How the Study Was Run
The researchers set it up as a pilot study.
It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.
The prognostic value of GH to predict 30-day mortality and 90-day functional outcome was assessed.
Favorable functional outcome was defined as Barthel Index score >85 points and Modified Rankin Scale <3 points.
What Was Measured
Endocrine alterations of the hypothalamic-pituitary-axis are one of the first measurable physiological changes in cerebral insults.
Within this pilot study, the researchers evaluated the prognostic value of GH in patients with acute intracerebral hemorrhage (ICH).
Topics PubMed links to this paper include Area Under Curve, Biomarkers, Cerebral Hemorrhage, Glasgow Coma Scale, Human Growth Hormone, Pilot Projects and Predictive Value of Tests.
What This Means in Plain Language
The paper is a pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 40 patients.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2011 (Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.